These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 12499482)
1. Cognitive activity and incident AD in a population-based sample of older persons. Wilson RS; Bennett DA; Bienias JL; Aggarwal NT; Mendes De Leon CF; Morris MC; Schneider JA; Evans DA Neurology; 2002 Dec; 59(12):1910-4. PubMed ID: 12499482 [TBL] [Abstract][Full Text] [Related]
2. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. Wilson RS; Mendes De Leon CF; Barnes LL; Schneider JA; Bienias JL; Evans DA; Bennett DA JAMA; 2002 Feb; 287(6):742-8. PubMed ID: 11851541 [TBL] [Abstract][Full Text] [Related]
3. Cognitive activity and cognitive decline in a biracial community population. Wilson RS; Bennett DA; Bienias JL; Mendes de Leon CF; Morris MC; Evans DA Neurology; 2003 Sep; 61(6):812-6. PubMed ID: 14504326 [TBL] [Abstract][Full Text] [Related]
4. Relation of blood pressure to risk of incident Alzheimer's disease and change in global cognitive function in older persons. Shah RC; Wilson RS; Bienias JL; Arvanitakis Z; Evans DA; Bennett DA Neuroepidemiology; 2006; 26(1):30-6. PubMed ID: 16254451 [TBL] [Abstract][Full Text] [Related]
5. The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment. Aggarwal NT; Wilson RS; Beck TL; Bienias JL; Berry-Kravis E; Bennett DA Neurocase; 2005 Feb; 11(1):3-7. PubMed ID: 15804918 [TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Bennett DA; Wilson RS; Schneider JA; Evans DA; Aggarwal NT; Arnold SE; Cochran EJ; Berry-Kravis E; Bienias JL Neurology; 2003 Jan; 60(2):246-52. PubMed ID: 12552039 [TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282 [TBL] [Abstract][Full Text] [Related]
9. Psychotic symptoms in Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: evidence for an association. Quaranta D; Bizzarro A; Marra C; Vita MG; Seripa D; Pilotto A; Sebastiani V; Mecocci P; Masullo C J Alzheimers Dis; 2009; 16(1):173-80. PubMed ID: 19158433 [TBL] [Abstract][Full Text] [Related]
10. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Devanand DP; Pelton GH; Zamora D; Liu X; Tabert MH; Goodkind M; Scarmeas N; Braun I; Stern Y; Mayeux R Arch Neurol; 2005 Jun; 62(6):975-80. PubMed ID: 15956169 [TBL] [Abstract][Full Text] [Related]
11. APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Bunce D; Fratiglioni L; Small BJ; Winblad B; Bäckman L Neurology; 2004 Sep; 63(5):816-21. PubMed ID: 15365129 [TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669 [TBL] [Abstract][Full Text] [Related]
13. Rate of memory decline in AD is related to education and occupation: cognitive reserve? Stern Y; Albert S; Tang MX; Tsai WY Neurology; 1999 Dec; 53(9):1942-7. PubMed ID: 10599762 [TBL] [Abstract][Full Text] [Related]
14. APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging. Klages JD; Fisk JD; Rockwood K Dement Geriatr Cogn Disord; 2003; 15(1):1-5. PubMed ID: 12457072 [TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. Hsiung GY; Sadovnick AD; Feldman H CMAJ; 2004 Oct; 171(8):863-7. PubMed ID: 15477624 [TBL] [Abstract][Full Text] [Related]
16. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years. Wattmo C; Wallin ÅK Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660 [TBL] [Abstract][Full Text] [Related]
17. APOE-epsilon4 is associated with memory decline in cognitively impaired elderly. Dik MG; Jonker C; Bouter LM; Geerlings MI; van Kamp GJ; Deeg DJ Neurology; 2000 Apr; 54(7):1492-7. PubMed ID: 10751265 [TBL] [Abstract][Full Text] [Related]
18. Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran. Raygani AV; Zahrai M; Raygani AV; Doosti M; Javadi E; Rezaei M; Pourmotabbed T Neurosci Lett; 2005 Feb; 375(1):1-6. PubMed ID: 15664112 [TBL] [Abstract][Full Text] [Related]
19. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. Mangialasche F; Solomon A; Kåreholt I; Hooshmand B; Cecchetti R; Fratiglioni L; Soininen H; Laatikainen T; Mecocci P; Kivipelto M Exp Gerontol; 2013 Dec; 48(12):1428-35. PubMed ID: 24113154 [TBL] [Abstract][Full Text] [Related]
20. Relation of cognitive activity to risk of developing Alzheimer disease. Wilson RS; Scherr PA; Schneider JA; Tang Y; Bennett DA Neurology; 2007 Nov; 69(20):1911-20. PubMed ID: 17596582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]